Our Resident Network
Meet Our Residents
LabCentral has generated significant interest from entrepreneurs and startups working on groundbreaking science who are eager to join LabCentral, a first-of-its-kind, fully resourced and equipped life-sciences laboratory space. Participants are chosen through a competitive process, where only the highest-potential applicants are selected in keeping with our mission.
Empowering patients to combat cancer
and preserve their quality of life.
Redefining drug delivery with on-target, sustained therapy using thermogelling polymers.
Absco Therapeutics unlocks the full potential of immune-modulating therapies using thermogelling polymers that transform from liquid to solid at body temperature, holding position on injection to create controlled-release drug depots optimal for immune education.
RNA medicines to treat, delay, and prevent diseases of the brain.
Targeted delivery of RNA medicines to the brain. By silencing the genes that cause harm, we aim to preserve minds, protect memories, and enable our loved ones to live healthier, longer lives.
Built on three pillars
- Next-generation RNA medicines
- Systemic administration and targeted brain delivery
- Precision and prevention to transform CNS treatment
Delivering therapeutics where the body needs them.
Directing a drug to the exact tissue that needs it is one of the hardest problems in medicine. We're solving it by decoding the body's glycan code — the sugar-based signatures unique to every tissue. Through high-throughput in silico and in vivo screening, we map tissue glycan signatures at cellular resolution and design peptides that recognize them.
Beyond Known Biology
The future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how.
Basecamp Research trains frontier AI models for therapeutic design. Our EDEN models are trained on BaseData, the world’s largest proprietary evolutionary genomic dataset: over 100 billion novel genes sourced through partnerships in more than 30 countries across all seven continents. We are now rapidly advancing a pipeline of EDEN-designed therapeutics towards clinical development. Headquartered in London, we have offices and labs in Boston.
Accelerate insights by connecting phenotype to genotype.
The Bifrost platform connects single-cell phenotypes including morphology, protein localization and production, cellular responses, and cell-cell interactions to underlying alleles at massive scale. Integrated software allows rapid progression from experiment to massive multi-parameter dataset to actionable insights.
About us
BioFeyn is a life sciences company, applying biomedical technology to make exponential advancements in food systems and sustainability. By working with leaders in aquaculture, agriculture, and cell culture, we’re enabling new solutions to improve both the health of people and the planet.
BioFeyn’s goal is to produce the most sustainable and nutrient-packed protein on the market.
By optimizing existing ingredients that are already proven to be safe and sustainable, we add value for farmers, feed suppliers, and the environment.
Using proven advancements from human biomedicine, BioFeyn is maximizing the impact of often scarce or expensive ingredients to improve animal health, reduce resource use, and minimize waste.
The BioFeyn platform of customizable ingredients delivers precision aquaculture and agricultural solutions where they are needed most.
Decoding the human protein interactome for safer, more targeted therapies.
95% of approved medicines target proteins as isolated entities, bluntly turning them on or off.
This modulates protein function globally, across pathogenic and healthy cellular pathways. It’s why essentially all medicines come with side effects.
We target protein interactions.
By targeting protein-protein interactions (PPIs), we aim to modulate only the pathogenic pathway, leaving healthy functions intact.
A Next Generation Approach To Healing
We offer a next-generation collagen platform that enables precise, injectable delivery of complete human collagen—advancing beyond first-generation therapeutics to enable rapid, effective healing. Our proprietary manufacturing and targeting approach represents a breakthrough in musculoskeletal injury treatment and wound repair.
BrilliantStrings is an early stage medical device company that has developed a breakthrough approach to accelerate healing of damaged connective tissues based on the direct, controlled-delivery of functional protein (e.g. complete human collagen – CHC) to the injury. The company's technology, supported by decades of academic research, has been demonstrated in animals to rapidly restore the strength of torn tendons. There are multiple applications in the orthopedic space, with rotator cuff disease comprising the largest market and our first target indication. The therapeutic can be administered via injection as well as in other formats (e.g. patches).
We discover molecules where biology actually happens.
Bullseye uses directed evolution inside living cells to discover functional molecules against challenging intracellular targets.
Rather than starting with a predefined mechanism or simplified assay, we generate and evaluate molecular diversity directly in cells, selecting for the biological outcome that matters.
While ASO therapeutics have been shown to be effective at treating disease by targeting disease genes at the RNA level intracellularly with long tissue resident half-life, they have been limited in their ability to treat neurological disease as they cannot effectively get across the blood brain barrier.
Centron Bio is transforming the treatment of neurological disorders with genetic medicines that cross the blood brain barrier.
Cha Therapeutics Inc. is an early-stage, privately held, Massachusetts-based biotechnology start-up developing a proprietary epigenetic therapy that improves cancer patient outcomes.
Our mission is to develop groundbreaking drug combinations to treat cancers that have evaded the immune system, particularly those driven by Wnt signaling.
Our unique approach leverages a combination of compounds designed to re-program tumor cells, making them more susceptible to immune checkpoint inhibitors and other immunotherapies.
Unlocking the full potential
of RNA medicine.
Collage Bio is developing a new class of programmable RNA therapeutics. Our platform combines AI-powered design with advanced polynucleotide engineering to enable precise, durable, and tunable control of gene expression. By bridging gene editing and traditional RNA approaches, we are opening a new frontier in programmable medicine.
Conveyor therapeutics aims to be the first company dedicated to expanding the knowledge of ADC design and development to novel payloads, targeting antigens, and indications. We seek to merge people, passion, and science to create therapeutics, which modulate intracellular targets with cellular precision, to restore health and save lives.
Our next generation antibody drug conjugate (ADC) platform will expand the use of ADCs beyond oncology and traditional cytotoxic payloads to immunology and immunosuppressive payloads. Conjugating payloads to an antibody offers a way to improve the therapeutic window of a given drug by directing it to the pathological cell type and reducing the level of systemic exposure of the free payload. With a few exceptions, most current generation ADCs are optimized for cell killing, which limits the applicability in areas outside of oncology. Limited development has gone into optimizing ADCs for other functions (e.g. interrupt kinase or transcription factor activity) or to have utility in cell types with lower expression of the targeted antigen.
Corellia launched out of Champions Oncology, a technology-enabled contract research organization, leveraging the world’s largest PDX Atlas and its living bank for AI-enabled target and drug discovery. Corellia is developing a large pipeline of innovative ADCs for patients with high unmet needs, at a pace and efficiency never achieved before.
About Crosslink
Extracellular adenosine triphosphate (eATP) is highly elevated in solid tumors making it a hallmark of cancers. Relative to normal tissue, tumors release eATP at high levels to help them develop and grow.
Crosslink has engineered a modular biologic domain which takes advantage of this difference to assemble therapeutics in tumors. Crosslink’s domain can be applied to virtually any therapeutic modality to improve tumor specific targeting and enhanced activity. We are currently focused on developing first-in-class/best-in-class applications in antibody drug conjugates and radioligand therapies.
DaCapo Brainscience, Inc. is built to create revolutionary, disease-modifying therapeutics for neurological diseases. DaCapo is fusing a unique understanding of biological systems, their induced pluripotent stem cell (iPSC)-based neuronal culture systems, their proprietary analyses of patient databases, and their pioneering AI/ML algorithms to create an integrated platform for disease-definition and target discovery. With this platform, DaCapo Brainscience can identify novel molecular subtypes of disease and corresponding drug targets for synucleinopathies (such as Parkinson's Disease and Lewy Body Dementia) and other neurodegenerative diseases.
ECI Therapeutics, LLC (ECI) is developing products from donated, pathogen-reduced human plasma. ECI's platform leverages serum-like plasma from donated human blood to promote the healing of epithelial (surface cell) disorders such as dry eye disease, ophthalmic burns, and chronic wounds. ECI has been issued robust patents protecting the formulation that combines serum-like plasma with a novel antimicrobial molecule (chitosan) to create products ranging from liquid eye drops to gels, ointments, contact lenses, contoured bandages, and wound dressings.
ECI's initial product will focus on dry eye disease. There are 22 million dry eye patients in the United States and of those only 8 million are treated, with 25% reporting satisfaction with their treatment. There is a need for more effective treatments with fewer side effects. We intend to fill this gap while growing the percent of diagnosed patients seeking treatment.
Evonik's strategic innovation unit and business incubator, Creavis, seeks to establish an innovation satellite to accelerate innovation in life science fields.
Evonik Health Care partners with the world's pharmaceutical, medical device and nutraceutical companies to transform complexity into value. Evonik is a leading system solution provider in nucleic acid-based medicine technologies. Research will include new excipients and delivery platforms to leverage the full potential of mRNA as a new therapeutic modality.
Many of the world’s largest and most innovative biopharmaceutical companies partner with Evonik to optimize their media platforms and processes. Our broad portfolio of cell culture ingredients and related services leverages six decades of industry leadership in highly purified amino acids. Research will include new technology platforms for cell culture media outside of dipeptides.
Evonik corporate venture capital will partner with the research team in Cambridge.
The future of biologics is genetic code expansion.
Any synthetic amino acid. Any protein. Any size.
Reshaping immunity through precision therapeutics.
Our aim is to develop a novel domain for immune recruitment for bispecific T cell engagers that specifically recruits immune cells in an activated, cytotoxic state. To do this, we are designing therapeutics that mimic antigens from common infectious diseases. In effect, our therapeutics will direct potent, existing immune responses for an infectious disease (e.g. SARS-CoV-2, influenza) towards a cancer, leading to a more precise and efficacious response.
Cell Therapy Meets Unprecedented Scalability
GC Therapeutics (GCTx) is harnessing the world’s first “plug-and-play” induced pluripotent stem cell (iPSC) cellular programming platform, TFome™ (Transcription-Factor-ome, pronounced as tee-eff-ome), to overcome the development and scaling complexities associated with cell therapy and improve patient access across a broad range of therapeutic areas.
GelMEDIX is a platform-based company focused on developing bioadhesive hydrogel drug depots to improve patient compliance and treatment outcomes in ophthalmology. GelMEDIX was founded based upon 8 years of academic work originating at Massachusetts Eye and Ear, Harvard Medical School, Northeastern University, and UCLA that was motivated by challenges in post-op and chronic treatment in ophthalmology.
General Biologics, Inc. uses the power of rational biological design to create new classes of therapeutics for treatment of unmet medical needs that have been underserved by the research community and overlooked by investors.
We have used this approach to develop a ground-breaking, first-in-class fusion protein therapeutic for treatment of hypoxia.
Gensaic is a phage-derived particle (PDP) gene delivery platform that addresses key limitations in the current gene therapy landscape. Unlike the market lead AAV technology, PDPs offer durable therapeutic efficacy via repeat administration, enable tissue-specific targeting, support massively scalable manufacturing, and can package any full-length human gene as a therapeutic (>20 kb).
HydroGene has a mission to bring gene therapy to all liver diseases. This can be accomplished with non-viral gene delivery, which would be safe, cheap, and redosable. Unfortunately, non-viral gene delivery with lipid nanoparticles has suffered of inefficiency from nuclear delivery of DNA cargo. As an alternative, HydroGene has solved how to scale hydrodynamic delivery inot the liver of large animals for the first time by leveraging the biliary system. HydroGene's approach is efficient, scalable, and safe in porcine and primate models and has exciting potential to treat rare and common diseases.
InGel Tx technology is an injectable biomimetic hydrogel platform engineered for the sustained release of stem cells and drugs in the eye, initially targeting regenerative medicine for retinitis pigmentosa, macular degeneration and geographic atrophy.
Research Area:
Biological Product
Cell Therapy
Interacta is building the data layer for AI native antibody discovery. While language and vision AI thrive on massive datasets biology is still operating with fewer than 15000 antibody antigen interactions. We are fixing that. Our platform screens over 100 million interactions per week in mammalian cells with functional relevance and at one thousandth the traditional cost.
This is not a CRO. It is a new operating model high quality non exclusive binder datasets across diverse targets ready to fine tune AI models or jumpstart discovery campaigns. We are doing for antibodies what Scale AI did for language and vision fueling the next generation of in silico biology.
Interon Laboratories is developing a new category of immunotherapy:
neuro-immunotherapy. Interon's exclusive technology brings together neurobiology and immunology, and is novel and non-invasive. This revolutionary science includes discoveries made by Interon's Co-Founders at MIT and Harvard Medical School, and was featured in journals including Nature, Science and Cell. Additionally, Interon has two lead programs to develop biologics and small molecule therapeutics for mitigating neurological and immune disorders.
Laurel is a preclinical biotechnology company developing next-generation antibody therapeutics for cardiovascular disease.
Our platform combines AI-enabled design with immune-derived discovery to generate modular single-domain and monoclonal formats that address crosstalk among cardiovascular, inflammatory, and metabolic pathways, with the goal of reducing patients’ at-home pharmacy burden.
Analyse single cell interactions and functional dynamics at scale.
We are developing a flexible platform that enables the direct, precise interrogation of single cell heterogeneity, interactions and functional behaviours. Across a broad range of disciplines from basic and translational research to drug discovery, we provide the freedom to accelerate discovery and apply novel biological insights.
Sparking immune regeneration via thymus regeneration.
1. Lightning Bio uses deep knowledge of immune cell generation and bioengineering to restore immunity damaged by toxins, disease, or age
2. Lightning Bio leverages the body's inherent regenerative capacity to create novel therapeutics for immune dysfunction
3. Lightning Bio's science works to replenish T cell diversity through modification of the body's cell factories
Coming Soon
Research Area:
Biological Product
Cell Therapy
Think outside the cell. Target the matrix.
Matrisome Bio is developing tools to deliver targeted therapies to the extracellular matrix (non-cellular components) of disease tissues such as tumors and fibrotic lesions in order to convert it from a barrier to a drug depot.
We're building curative genetic medicines for kidney and pancreatic diseases.
Nephrogen is a Stanford biotech spinout commercializing an AI screening platform to solve gene delivery for serious diseases. Delivery is the central bottleneck in genetic medicine. As of Q1 2026, there are 903 clinical-stage genetic medicines, but almost zero target the kidney or pancreas, a gap driven primarily by the lack of efficient delivery vehicles for reaching these tissues.
These improved delivery vehicles unlock curative genetic therapy for kidney and pancreatic diseases, which affect 1 in 7 Americans, account for a significant share of Medicare spending, and have no approved gene-based therapies today.
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Their innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors.
At Noara Therapeutics, we're at the forefront of RNA-based therapeutics, leveraging the power of machine intelligence to engineer 3rd generation circular RNAs (nRNAs). By integrating advanced structural biology, proprietary high throughput screening, and cutting edge artificial intelligence, we overcome critical challenges in RNA therapies such as immune activation and stability. Our AI-driven platform empowers the precise design of immunosilent and highly stable RNAs that unlock transformative solutions for chronic diseases by protein replacement. With a team of world class experts and a technology edge in AI-enhanced RNA engineering, Noara is set to lead the next wave of innovation in RNA medicine.
Nucyrna Therapeutics aims to establish a new paradigm of RNA-targeting therapeutics by co-targeting nuclear and cytoplasmic RNA via one oligonucleotide drug.
Oddity Labs is a biotechnology research and development center to power Oddity product innovations through the discovery and development of molecules, probiotics, peptides, and other biological modalities. We are developing the world's most advanced phenotypic database to understand the biological mechanisms that drive cellular behavior for beauty and wellness indications.
We will be developing injectable microparticles containing drugs (vaccines, other API's) that have programmable release kinetics and time points. These microparticles provide self-boosting vaccines, replace multiple injections with a single injection, and also enable long term storage of drugs without the need for cold chain.
Orthrus is pioneering antigen-specific immune tolerance to treat autoimmune and allergic diseases at their root. Built on our proprietary Tolerance platform, we create nanobody-antigen-drug conjugates that retrain the immune system to ignore disease-driving antigens, without the need for broad immunosuppression. Unlike conventional therapies that only manage symptoms, Orthrus aims to deliver durable, disease-modifying treatments.
Overture Therapeutics is engineering antibody-based therapies that target the root causes of obesity, not just appetite. Our programs act directly on adipose and muscle tissue to drive safer, more sustainable weight loss while preserving metabolic health, offering a differentiated alternative or complement to GLP-1 therapies.
At Polbionica, we develop breakthrough technologies in biofabrication. We provide a comprehensive technological ecosystem for the production and cultivation of advanced tissue structures, organoids, and cellular scaffolds created using 3D bioprinting. Our flagship project is the Bionic Pancreas-ATMP® — the world’s first functional organ bioprinted from living cells, capable of physiological insulin and glucagon secretion. The technology is being developed as a novel therapeutic strategy for type 1 diabetes and chronic pancreatitis. Our innovations support and accelerate research in regenerative medicine, personalized therapies, and drug testing, opening new opportunities for the development of advanced treatment strategies. We equip scientists and clinicians with tools for designing and evaluating tissue models used in preclinical research and therapeutic development.
Creating transformative medicines for people with inflammatory diseases.
At Promakhos, we utilize unique insights from patient samples to develop medicines that address the root cause of inflammatory diseases. Instead of blocking the immune system, our medicines aim to restore the natural ability of the body to manage inflammation and heal.
Transforming inflammatory disease treatment
Though inflammation is normally a healthy part of the body’s response to injury or infection, some people experience a dysfunctional immune response. The resulting chronic inflammation can damage the body and lead to further disease. Current therapies for chronic inflammatory diseases such as Crohn’s disease, ankylosing spondylitis and psoriasis often work by suppressing the immune system, and treat symptoms rather than addressing the root causes of the disease. However, only 25% of patients benefit from these therapies long term. What if – instead of working against the immune system – we figured out how to restore its balance and function?
Promakhos Therapeutics aims to do just this. Founded in the spring of 2021 and based in Boston, Massachusetts, we develop transformative therapies that restore the function of the immune system, allowing the body to control inflammation and heal.
Coming Soon
Research Area:
Drug Discovery / Development
Recombinant Therapeutic Protein
RASyn is developing a suite of integrative technologies, leveraging unparalleled high-throughput sequencing, cell free protein synthesis and functional screening coupled with computational protein design and machine learning. RASyn's platform will power predictive diagnostics analytics, enhance novel target discovery as well as unlock novel therapeutic design spaces across multiple modalities.
A New Genetic Logic for Cancer Therapy
Targeted therapies have transformed precision oncology, but they lack the long-term durability needed to cure advanced tumors.
At Red Ace, we take a different approach: we reprogram tumors from the inside out to create entirely new therapeutic opportunities.
By rewiring cancer cells with synthetic vulnerabilities, our platform can overcome resistance and enable treatments that last.
At Regatta Bio, we are advancing the next generation of regulatory T cell (Treg) therapies to address some of the most pressing challenges in immune health. Our mission is to develop scalable, targeted, and durable treatments for conditions like chronic Graft-versus-Host Disease, solid organ rejection, and autoimmune disorders by overcoming the limitations of traditional immunosuppression.
Ribonaut Therapeutics is developing a novel small molecule platform capable of specifically degrading RNAs for the treatment of human diseases. Ribonaut's approach leverages the work of academic founder, Matthew Disney - Chair of the Department of Chemistry at Scripps Florida, and his foundational insights into the targeted recruitment of RNAses to specific RNA structural motifs using small molecules.
Research Area:
Drug Discovery / Development
Small Molecules
Riboway specializes in controlling how proteins are made by targeting RNA. Our smart RNA-targeting technology enables us to upregulate, downregulate, activate, or inhibit target proteins, depending on therapeutic needs. This flexibility is driven by our AI-based platform that decodes RNA regulation to identify druggable angles. So far, we’ve successfully validated 5 out of 5 targets attempted.
Our pipeline focuses on neurodegenerative diseases, including a first-ever ASO designed to activate protein function. We are currently raising seed funding as well as looking for partnership/BD out-licensing opportunities.
WE ARE SATURNUS BIO
One in three patients living with heart failure has a monogenic mutation that drives disease.
We are addressing genetic drivers of heart failure using targeted, non-viral gene-modulating therapies.
Our vision is to transform the lives of millions with a portfolio of first-in-class disease-modifying medicines
Our team of life science professionals has decades of experience discovering and developing medicines for patients living with cardiovascular and genetic diseases.
Positioned at the crossroads of science and beauty, Strand Research’s mission is to address the most significant challenges in hair care faced by consumers today. We develop novel compounds, including small molecules, peptides, and polymers, with a science-first approach, and are committed to innovation through data.
Synolo Therapeutics, an early-stage biotechnology company launched by RA Capital, is pioneering the development of precision-targeted immunotherapies for cancer. Powered by computational protein design and proprietary technologies which yield biological data sets at unprecedented scale and resolution, we are building a pipeline of first-in-class multi-specific biologics with novel functionalities. Synolo was founded by pioneers in the field of protein design and engineering, synthetic biology, DNA sequencing, immunology, and biologics drug discovery and development.
The Termeer Institute is a catalyst for innovation that brings life-changing treatments to patients worldwide.
We support and empower brilliant life science innovators through values-driven leadership programming including mentorship, network development and thought leadership to advance groundbreaking, patient-centric solutions.
Rewriting RNA’s regulatory code to disrupt tumor survival
For more than a decade, our research has mapped how RNA methylation governs cellular survival. That work uncovered a critical dependency in cancer cells on the demethylase FTO.
Today, Tinos Tx translates that insight into first-in-class small molecule inhibitors designed to destabilize tumor-driving RNA and collapse cancer from within.
Viska.Bio Therapeutics induces Immunogenic Cell Death by treating cancer with a Fusion Protein between a tumor specific antibody and the enzyme Xanthine Oxidase. This produces superoxide in the tumor microenvironment oxidizing lipids which are incorporated into the lysosome which then becomes leaky releasing degradative enzymes which induce endopepsis - or cellular internal digestion. One result is that calreticulin, the eat me signal for DCs, migrates to the cell surface initiating the immunogenic feature. ODIN Therapeutics has produced a fusion protein to EGFR and shown that it produces the classic markers of Immunogenic Cell Death.
Volnay is building transformative and commercially viable cell & gene ventures centered on product development and technology innovation.
We build next-generation manufacturing technologies and integrate them with high value therapeutic assets to deliver commercially viable therapeutic products. Our goal is to unleash the full potential of cell and gene therapies for patients worldwide.
WhiteLab Genomics is a pioneering startup leveraging Artificial Intelligence to accelerate and mitigate risks in early-stage research and development pipeline for genomic medicine. We are actively engaged in partnerships with renowned academic institutions (Genethon, Brain Institute), as well as small and mid-sized biotech (Flagship Pioneering, SIREN biotech) and pharmaceutical companies (e.g. Sanofi), aimed at addressing critical challenges in the biopharma industry for target discovery, payload, and vector engineering and bioproduction. We are collaborating with Sanofi to develop new gene therapies in ophthalmology (targeting microglia in the CNS) and rare disease.
By bringing together the power of computer sciences (e.g. ML, GenAI) and biology, we help our partners to reach their target product profile, faster, in leaner ways. We have developed a proprietary platform including algorithms and databases to improve the design of therapeutic candidates for enhanced safety and efficacy. It includes vectors optimisation such as adeno-associated virus (AAV) and lentivirus, or non-viral like LNP. WLG synergistically combines in-house biomarker cellular atlas, computer science techniques with bioinformatic methods like transcriptomic analysis and structure prediction. WLG employs computational and structural biology to predict the most pertinent receptor-ligand interactions for specific targets, be it organs or cells. For instance, in the context of improved AAV transduction, WhiteLab strives to identify membrane-associated receptors and ligands that are highly specific to a tissue as a potential target. A key differentiator regarding our approach is that we can identify biomarkers that are highly specific to a cell type in over 850 cells in the body. This enables our AI platform to design the best vector to bring the right therapeutic sequence into the cells expressing a specific phenotype.
Enzyme replacement therapies have the potential to transform patient lives but the modality suffers from limitations including immunogenicity, short half life, and low activity. We aim to develop a platform that addresses these limitations with an initial focus on rare inborn errors of metabolism. The platform leverages the Skyhook (RASyn) platform.